Navigation Links
HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP Congress
Date:9/9/2011

AD Pump, and also the breadth of HVAD System adoption outside the United States."

About HeartWare International

HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® Pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.

Forward-Looking Statements

This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.  All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the timing and progress of, and presentation of data related to, clinical and preclinical trials, expected timing of regulatory f
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. HeartWare to Report 2010 Fourth Quarter and Year-End Financial Results
2. HeartWare to Present at the 22nd Annual Piper Jaffray Health Care Conference
3. HeartWare International, Inc. Temporary Suspension of Trading
4. U.S. Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International
5. Enterologics Completes Acquisition of BioBalance Corp and Probiotic Product From New York Health Care, Inc
6. TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
7. Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers
8. AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API
9. Peloton Therapeutics Completes $18 Million Series A Financing
10. Sinapis Pharma Completes Phase I Trial
11. MiMedx Group Completes $5,000,000 Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013   Oligomerix, Inc. ... of disease modifying therapeutics for Alzheimer,s disease (AD) ... of its Series B financing, which includes both ... that would represent approximately $2.8M in new investments ... investors supported the raise. Funding ...
(Date:5/22/2013)... 2013 Genedata, a leading provider ... discovery, and life science research, today announced AB ... as its bioinformatics platform for strain genome data ... provide AB Enzymes, one of the world’s oldest ... of Genedata Selector accompanied by bioinformatics consulting services. ...
(Date:5/22/2013)... MN (PRWEB) May 22, 2013 ... Medical Supplies Pty Ltd are pleased to announce ... is the Australian and New Zealand distributor of DrugCheck® ... V8 Supercar Team participated in the Austin 400 May ... entered into an agreement that involves each car of ...
(Date:5/22/2013)... The ability to sequence genomes has ... encode. There are now a suite of applications ... protected fragments) that dramatically expand our ability to ... Dr. Jonathan Weissman, an Investigator with the University ... Institute, who will present recent applications of their ...
Breaking Biology Technology:Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Monitoring Protein Synthesis One Codon at a Time Through Ribosome Profiling, a Webinar Hosted by Xtalks 2
... educated nearly 80,000 patients in over 30 states on ... disease and treatment options since 1997, DEERFIELD, Ill., ... Baxter Healthcare Corporation,s Kidney Patient,Educator (KPE) program, an ambitious ... disease (CKD) and treatment options to,nearly 80,000 kidney disease ...
... at 11:45 am ET on November 8, 2007, ... (Nasdaq: TARG ) today announced its participation,in ... Conference, taking place November 8, 2007 at the,Hilton ... Officer of Targanta, will be presenting at 11:45 ...
... MNKD ) today announced results from a ... GLP-1 (glucagon-like peptide) on Technosphere,particles that is delivered ... as an open-label, dose escalation, controlled safety and,tolerability ... was assigned to one of five dose levels ...
Cached Biology Technology:Baxter Kidney Patient Education Program Celebrates Tenth Anniversary 2Baxter Kidney Patient Education Program Celebrates Tenth Anniversary 3Baxter Kidney Patient Education Program Celebrates Tenth Anniversary 4Targanta to Present at 9th Annual Mass Opportunities Investment Conference 2MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation 2MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation 3MannKind Announces Positive Results from a Phase 1a Study of a GLP-1 Formulation 4
(Date:5/22/2013)... health effects from disposal of millions of rechargeable ... recommend stronger government policies to encourage recovery, recycling ... the conclusion of a new paper in the ... , Oladele A. Ogunseitan and colleagues point out ... everything from smart phones to components in new ...
(Date:5/22/2013)... 2013 Early screening for prostate cancer could become ... for women, thanks to UC Irvine research published today ... . , After more than a decade of work, ... identify clinically usable markers for prostate cancer in urine, ... with greater accuracy and at dramatically lower cost. The ...
(Date:5/21/2013)... Using a "patient monitoring" device attached to a whale ... time how fishing lines changed a whale,s diving and ... whales, ability to eat and migrate, depletes their energy ... can result in a slow death. , The scientists ... a Dtag to a two-year-old female North Atlantic right ...
Breaking Biology News(10 mins):UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3Study reveals how fishing gear can cause slow death of whales 2Study reveals how fishing gear can cause slow death of whales 3
... in the Indian Ocean and collaborating with researchers at the ... night cameras to capture the first known occurrence of a ... is this the first time this behaviour has been documented ... who are better known for eating plants but the ...
... COLLEGE STATION - Mango. If you know little about ... stop certain colon and breast cancer cells in the lab. ... AgriLife Research food scientists, who examined the five varieties most ... Though the mango is an ancient fruit heavily ...
... New standards to help ensure the quality and ... infant formulas and a variety of functional foods are ... (FCC), an internationally recognized compendium of quality standards for ... present in breast milk and commonly added to infant ...
Cached Biology News:First known instance of a cricket as an orchid pollinator captured on film by Kew scientist 2Mango effective in preventing, stopping certain colon, breast cancer cells 2Quality and safety of infant formulas, functional foods enhanced by new standards 2Quality and safety of infant formulas, functional foods enhanced by new standards 3
... the LVF-HL, LVF-CUVADPT, FHS-LVF, and the CVD-Diffuse ... low-pass Linear Variable Filters to create the ... center wavelength and adjustable bandpass. Each filter ... blocking band (99.8%). These filters -- ...
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
Request Info...
MW5...
Biology Products: